Abstract: The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising guide-binding adaptors each associated with at least one destabilization domain (DD), along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses therefor.

Abstract: The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising CRISPR enzymes associated with at least one destabilization domain (DD) and photocaged stabilization ligands with at least one photocage molecule, along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses thereof.

Abstract: Compositions and methods for inhibiting the activity of RNA-guided endonucleases, and methods for identifying such compositions are included. Methods of treatment using the inhibitory compounds, formulations and methods are also detailed, as well as control of nucleic acid editing systems and methods using said compounds.

Abstract: Engineered ionophores capable of increased metal ion transport across hydrophobic membranes and/or reduced metal ion binding affinity, pharmaceutical compositions thereof, kits thereof, ion-selective membrane devices thereof, and methods of use thereof. Hydrophobic membranes can be biological, e.g., cell membranes, or nonbiological, e.g., ion-selective membranes. Engineered ionophores can comprise a metal ion chelator group comprising: a polar binding site having binding atoms to form a metal ion chelate complex; and one or more shielding group(s) in proximity to the binding atoms. Shielding groups can increase the hydrophobic membrane permeability and reduce the binding affinity of the chelate complex. Methods of use can comprise contacting said membranes with said engineered ionophores, metal ion chelate complexes thereof, pharmaceutical compositions thereof, the components of kits thereof, or the like, or any combination thereof.

Abstract: The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to ?-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to ?-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in ?-cells.

Abstract: The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to ?-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to ?-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in ?-cells.

Abstract: Compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors.

Abstract: The embodiments disclosed herein utilize fluorescence polarization based preliminary screen to identify a putative set of Cas inhibitors from an initial set of candidate inhibitors. The primary screening assay is followed by secondary screening assay to validate the putative set of inhibitors selected by the preliminary screen. In some embodiments, the present disclosure includes compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors.

Abstract: The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising CRISPR enzymes associated with at least one destabilization domain (DD) and photocaged stabilization ligands with at least one photocage molecule, along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses thereof.

Abstract: The disclosure includes non-naturally occurring or engineered DNA- or RNA-guided nuclease systems, comprising guide-binding adaptors each associated with at least one destabilization domain (DD), along with compositions, systems and complexes involving such systems, nucleic acid molecules and vectors encoding the same, delivery systems involving the same, uses therefor.

Abstract: Compositions and methods for inhibiting the activity of RNA-guided endonucleases, and methods for identifying such compositions are included. Methods of treatment using the inhibitory compounds, formulations and methods are also detailed, as well as control of nucleic acid editing systems and methods using said compounds.

Abstract: The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to ?-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to ?-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in ?-cells.

Abstract: The embodiments disclosed herein utilize fluorescence polarization based preliminary screen to identify a putative set of Cas inhibitors from an initial set of candidate inhibitors. The primary screening assay is followed by secondary screening assay to validate the putative set of inhibitors selected by the preliminary screen. In some embodiments, the present disclosure includes compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors.

Abstract: Compositions and methods are provided for the inhibition of the function of RNA guided endonucleases, including the identification and use of such inhibitors.